



PMAC | PRINCE MAHIDOL
AWARD CONFERENCE **2022**

S6

**PANDEMIC PREPAREDNESS AND RESPONSE: STOPPING THE NEXT
OUTBREAK BEFORE IT BECOMES A PANDEMIC**

| BACKGROUND

Despite years of planning and investment since the 2005 International Health Regulations were published by WHO, the COVID-19 pandemic exposed how remarkably unprepared the world was to control the spread and recover from the effects of SARS-CoV-2. Among several analyses of what went wrong with the response, in May 2021, The Independent Panel for Pandemic Preparedness & Response issued a comprehensive main report of its findings and recommendations for action to curb the COVID-19 pandemic and to ensure that any future infectious disease outbreak does not become another catastrophic pandemic.

This PMAC-2022 parallel session will address some elements central to stopping the next outbreak before it becomes a pandemic. Panelists will be asked to identify enabling factors and likely barriers; and to address specific action steps to achieve the goal of preventing another pandemic.

Key themes are:

1. Investing in preparedness and coordination now to prevent or mitigate the next crisis
2. The future of broadly-acting antiviral agents and universal vaccines for coronaviruses, influenza and other high-consequence infectious agents
3. Building global manufacturing capacity for rapid antiviral and vaccine production, including mRNA-based vaccines, towards full global access
4. Establishing a pre-negotiated global platform for access to vaccines, tools and supplies

| OBJECTIVES

To identify enabling factors and likely barriers; and to illuminate specific action steps to achieve the goal of preventing another pandemic.



Panelist

Rick Bright

CEO, Pandemic Prevention Institute

and Senior Vice President, Pandemic Prevention, The Rockefeller Foundation
United States of America

Rick Bright is currently the Chief Executive Officer of the Pandemic Prevention Institute (PPI) at The Rockefeller Foundation. Dr. Bright leads the development of the Foundation's pandemic data-to-action platform that integrates modern technology, data analytics and global partners to help the world detect, prevent, and mitigate pandemic threats to achieve containment as quickly as possible.

Prior to this role, he served as the Deputy Assistant Secretary for Preparedness and Response and the Director of the Biomedical Advanced Research and Development Authority (BARDA), in the U.S. Department of Health and Human Services. Dr. Bright has also gained extensive experience in the biotechnology industry where he served in senior leadership and executive management roles. He has held senior scientific leadership positions in non-governmental organizations where he championed innovative vaccine development and expanded vaccine manufacturing capacity to multiple developing countries. He also spent a decade in vaccine, therapeutics, and diagnostics development at the Centers for Disease Control and Prevention. For this work, Dr. Bright received the Charles C. Shepard Science Award for Scientific Excellence.

Dr. Bright serves as an international subject matter expert in biodefense, emergency preparedness and response, pharmaceutical innovation, vaccine, drug and diagnostics development and served as an advisor to the Biden Administration, World Health Organization, the Coalition for Epidemic Preparedness Innovations (CEPI) and the National Academies of Sciences, Engineering & Medicine Forum on Microbial Threats. Dr. Bright serves as a Sr. Fellow at the Foreign Policy Association.

Dr. Bright received a Ph.D. in Immunology and Molecular Pathogenesis from Emory University and a B.S. magna cum laude in Biology and Physical Sciences from Auburn University at Montgomery.